Baillie Gifford & Co. Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Baillie Gifford & Co. lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,889,571 shares of the company's stock after selling 3,568,512 shares during the quarter. Moderna comprises approximately 1.2% of Baillie Gifford & Co.'s portfolio, making the stock its 22nd biggest position. Baillie Gifford & Co. owned 10.11% of Moderna worth $1,617,028,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB lifted its position in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Blue Trust Inc. raised its position in shares of Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after purchasing an additional 388 shares during the last quarter. EMC Capital Management raised its position in shares of Moderna by 311.2% in the 4th quarter. EMC Capital Management now owns 1,250 shares of the company's stock worth $52,000 after purchasing an additional 946 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after purchasing an additional 317 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ:MRNA traded down $2.17 during mid-day trading on Thursday, reaching $33.73. 11,404,403 shares of the company traded hands, compared to its average volume of 12,914,939. The company's 50 day moving average price is $38.17 and its 200-day moving average price is $53.20. The firm has a market cap of $12.98 billion, a PE ratio of -3.63 and a beta of 1.59. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on MRNA. UBS Group lowered their price target on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research report on Wednesday. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $111.00 to $45.00 in a research report on Tuesday. Berenberg Bank lifted their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Finally, Evercore ISI decreased their target price on Moderna from $60.00 to $50.00 and set an "in-line" rating for the company in a research report on Monday, January 27th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Moderna has an average rating of "Hold" and a consensus price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.